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A B S T R A C T   
Bumped kinase inhibitors (BKIs) target the apicomplexan calcium-dependent protein kinase 1 (CDPK1). BKI- 
1748, a 5-aminopyrazole-4-carboxamide compound when added to fibroblast cells concomitantly to the time 
of infection, inhibited proliferation of apicomplexan parasites at EC50s of 165 nM (Neospora caninum) and 43 nM 
(Toxoplasma gondii). Immunofluorescence and electron microscopy showed that addition of 2.5 μM BKI-1748 to 
infected HFF monolayers transformed parasites into multinucleated schizont-like complexes (MNCs) containing 
newly formed zoites, which were unable to separate and form infective tachyzoites or undergo egress. In 
zebrafish (Danio rerio) embryo development assays, no embryonic impairment was detected within 96 h at BKI- 
1748 concentrations up to 10 μM. In pregnant mice, BKI-1748 applied at days 9–13 of pregnancy at a dose of 20 
mg/kg/day was safe and no pregnancy interference was observed. The efficacy of BKI-1748 was assessed in 
standardized pregnant mouse models infected with N. caninum (NcSpain-7) tachyzoites or T. gondii (TgShSp1) 
oocysts. In both models, treatments resulted in increased pup survival and profound inhibition of vertical 
transmission. However, in dams and non-pregnant mice, BKI-1748 treatments resulted in significantly decreased 
cerebral parasite loads only in T. gondii infected mice. In the T. gondii-model, ocular infection was detected in 10 
out of 12 adult mice of the control group, but only in 3 out of 12 mice in the BKI-1748-treated group. Thus, 
TgShSp1 oocyst infection is a suitable model to study both cerebral and ocular infection by T. gondii. BKI-1748 
represents an interesting candidate for follow-up studies on neosporosis and toxoplasmosis in larger animal 
models.   
1. Introduction 
The apicomplexan parasites Neospora caninum and Toxoplasma gondii 
cause important diseases in farm animals and have an enormous global 
economic impact. N. caninum is one of the major infectious causes of 
abortion and stillbirth in cattle (Dubey et al., 2017). T. gondii has a 
higher impact due to infections in a wider range of hosts, including 
humans (Webster and Dubey, 2010). The two protozoans exhibit life 
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cycles comprised of three distinct stages: (i) sporozoites, encapsulated in 
oocysts that are formed within their respective definitive hosts (feline 
for T. gondii, canine for N. caninum) and which are shed with the feces; 
(ii) rapidly proliferating tachyzoites causing acute disease that can be 
vertically transmitted; and (iii) slowly proliferating bradyzoites, which 
form tissue cysts, and persist for years without clinical signs (Dubey 
et al., 2017). Intermediate hosts get infected by oral uptake of oocysts or 
by ingestion of tissue cysts. In an immunocompetent host, conversion to 
bradyzoites occurs, and cysts are formed mostly within the brain and 
muscle tissue (Webster and Dubey, 2010; Dubey et al., 2017). At this 
stage, the parasites do not cause disease. However, problems can occur 
during pregnancy or immunosuppression. Toxoplasmosis is a major 
abortion-causing pathogen in sheep and other farm animal, and primary 
infection in pregnant women with T. gondii can lead to vertical trans-
mission, fetal malformations, or abortion (Hampton, 2015). In patients 
undergoing immunosuppressive disease or therapy, reactivation of 
bradyzoites and re-differentiation into tachyzoites often cause serious 
pathology. No cases of human N. caninum infection have been reported 
to date, but neosporosis-induced abortion and disease in cattle and other 
ruminants is a major economic burden (Aguado-Martínez et al., 2017). 
Calcium-dependent protein kinase 1 (CDPK1), represents a prom-
ising drug target that is found in numerous apicomplexans. Bumped 
kinase inhibitors (BKIs) specifically inhibit the activity of CDPK1. The 
importance of CDPK1 was first demonstrated in T. gondii gliding 
motility, exocytosis, invasion and egress (Kieschnick et al., 2001; 
Nagamune et al., 2008). Crystal structures of T. gondii CDPK1 revealed a 
glycine gatekeeper residue at the entry of the ATP binding pocket 
(Murphy et al., 2010; Ojo et al., 2010, 2014; Wernimont et al., 2010). 
This allows selective targeting of CDPK1 with BKIs, taking advantage of 
a hydrophobic pocket that is opened up next to the glycine gatekeeper 
(Bishop et al., 1998; Bishop and Shokat, 1999). Mammalian protein 
kinases almost uniformly have gatekeeper sidechains that are larger 
than the hydrogen in glycine and thus are usually not inhibited by BKIs 
(Keyloun et al., 2014). 
Several BKIs have shown promising efficacy against N. caninum and 
T. gondii in vitro and in vivo. Toxoplasmosis and neosporosis are systemic 
infections, thus for optimal therapy, these compounds should penetrate 
the blood-brain barrier, the placenta and the eyes (Arnold et al., 2017). 
For two pyrazolopyrimidine (PP) BKI compounds, BKI-1294 (Ojo et al., 
2014; Winzer et al., 2015; Müller et al., 2017a; Sánchez-Sánchez et al., 
2019a) and BKI-1553 (Müller et al., 2017b; Sánchez-Sánchez et al., 
2018a), proof of concept has been demonstrated in small and large an-
imal models of toxoplasmosis and neosporosis. 
This study reports on another member of the BKI-class, the 5-amino-
pyrazole-4-carboxamide (AC) compound BKI-1748. BKI-1748 has a 
number of attractive efficacy and safety features. It inhibits TgCDPK1 
and NcCDPK1 enzyme activities at low nM-concentrations and has 
excellent pharmacokinetics after oral dosing with 25 mg/kg in mice, 
achieving 38.6 μM maximum concentration with an area-under-the- 
curve of 11412 min*μmol/L and half-life of 164 min, allowing once 
daily-dosing (Huang et al., 2019). Solubility is > 100 μM in aqueous 
solution at pH 6.5 and 2.0, and BKI-1748 is only 80% 
mouse-plasma-bound (Huang et al., 2019). BKI-1748 exhibited efficacy 
against acute and chronic T. gondii infection with RH- and 
Prugniaud-strains, respectively (Hulverson et al., 2019), no detectable 
inhibition at 30 μM of human-ether-à-go-go (hERG) K+ -channel, a 
cardiovascular risk (Huang et al., 2019), no inhibition at 10 μM against 
SRC, a mammalian protein kinase with a small gatekeeper residue, 
suggesting little off-target kinase inhibition (Hulverson et al., 2019), and 
favorable rat and dog cardiovascular safety testing, with only minor 
abnormalities detected at 18 μM and above (Choi et al., 2020). These 
features favor further studies on this compound for efficacy in mouse 
pregnancy against Toxoplasma and Neospora. 
2. Material and methods 
2.1. Cell culture media, biochemicals, BKI-1748 
Culture media were from Gibco-BRL (Zürich, Switzerland), bio-
chemicals from Sigma (St. Louis, MO, USA). BKI-1748 was originally 
synthesized in the Department of Biochemistry of the University of 
Washington, USA (Hulverson et al., 2019) and scaled up by WuXi Apptec 
Inc., Wuhan, China to >98% purity by LC/MS-MS and NMR and shipped 
as powder. For in vitro studies, stock solutions of 20 mM were prepared 
in dimethyl-sulfoxide (DMSO) and stored at − 20 ◦C. 
2.2. Host cells and parasites 
Human foreskin fibroblasts (HFF; PCS-201-010™) and BALB/c 
dermal fibroblasts (CELLNTEC AG, Bern, Switzerland) were maintained 
as described (Winzer et al., 2020a). The N. caninum Spain-7 isolate 
(NcSpain-7) and the β-galactosidase expressing strain Nc-β-gal were 
maintained in HFF (Aguado-Martínez et al., 2016). T. gondii Me49 and 
T. gondii β-gal tachyzoites were cultured as previously described (Winzer 
et al., 2015). T. gondii oocysts of the type II isolate TgShSp1 
(Sánchez-Sánchez et al., 2019b) were obtained from Complutense Uni-
versity of Madrid, Spain, and stored at 4 ◦C until use. 
2.3. Cytotoxicity and anti-T. gondii/anti-N. caninum efficacy assessments 
HFF cytotoxicity and in vitro efficacy assessments against Tg-β-gal 
and Nc-β-gal tachyzoites (EC50 determinations) were done as described 
earlier (Barna et al., 2013; Anghel et al., 2020). EC50 values were 
calculated after the logit-log transformation of relative growth and 
subsequent regression analysis by use of the corresponding software tool 
in the Excel software (Microsoft, Seattle, WA). 
2.4. Microscopy 
Immunofluorescence labeling was done as described previously 
(Winzer et al., 2020b). In short, 2 × 104 HFF were grown on glass 
coverslips and were infected with 2 × 104 NcSpain-7 or TgMe49 
tachyzoites for 2 h at 37 ◦C/5%CO2. The medium was replaced and 
supplemented with 2.5 μM BKI-1748, or medium without compound. 
Infected cells were cultured for a maximum of 9 days, with medium 
plus/minus drug being changed daily. On days 2, 6 and 9, cells were 
fixed in 3% paraformaldehyde in PBS (pH 7.2) for 10 min, and per-
meabilized in a 1:1 solution of pre-cooled methanol/acetone at − 20 ◦C. 
Following rehydration, nonspecific binding sites were blocked in 
PBS/3% bovine serum albumin (BSA) overnight at 4 ◦C. The monoclonal 
mouse anti-NcSAG1 (1:1000), anti-mouse fluorescein-isothiocyanate 
(FITC) (1:300), polyclonal rabbit anti-IMC1 (1:500), and anti-rabbit 
tetramethyl-rhodamine-isothiocyanate (TRITC) (1:300) were applied 
sequentially. Finally, samples were mounted in H-1200 Vectashield 
mounting medium (Vector Laboratories, Burlingame, CA, USA) con-
taining 4,6-diamidino-2-phenylindole (DAPI). 
For transmission-(TEM) and scanning-electron microscopy (SEM), 
HFF grown in T25 or T125 tissue culture flasks were exposed to 1 × 107 
NcSpain-7 tachyzoites in culture medium (4 h, 37 ◦C/5%CO2). Then 
cultures underwent continuous treatment with 2.5 μM BKI-1748 for 4 
days. TEM preparations were carried out as previously described 
(Winzer et al., 2015). Ultrathin sections were placed onto 
formvar-carbon-coated grids (PLANO, Wetzlar, Germany), and samples 
were observed on a Philips CM12 TEM operating at 80 kV. For SEM, 
MNCs and tachyzoites were separated from host cell debris by 
Sephadex-G-25-chromatography and were fixed and processed as 
described (Winzer et al., 2020c). They were placed onto glass coverslips, 
sputter-coated with gold and inspected on a Zeiss Gemini450 SEM 
operating at 5 kV. 
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2.5. Ethics statement 
Animal experiments were approved by the Animal Welfare Com-
mittee of the Canton of Bern (licenses BE101/17 and BE117/2020). 
Animals were handled in strict accordance with practices to minimize 
suffering. BALB/c and CD1 mice, 6 weeks of age, were purchased from 
Charles River (Sulzberg, Germany), were maintained in a common room 
under controlled temperature and a 14 h/10 h light/dark cycle and were 
housed in the facility for two weeks for adaptation prior to the 
experiments. 
2.6. Pregnancy interference test in BALB/c mice 
Twenty-four female BALB/c mice were estrus-synchronized for 3 
days (Winzer et al., 2015) and 1 male and 2 females per cage were 
housed together for 72 h. After mating, males were removed, and female 
mice were randomly allocated to 4 experimental groups (6 mice/group; 
2 females/cage). BKI-1748 was supplied by oral gavage at 50, 20 or 5 
mg/kg/day in 100 μl corn oil on day 9–13 post-mating (Winzer et al., 
2015; Müller et al., 2017a). The placebo group received 100 μl corn oil 
for 5 consecutive days. One hour after the final drug application, blood 
from the tail vein of mice treated with 20 mg/kg and 5 mg/kg BKI-1748 
was collected and transferred into heparin-coated tubes. After inverting 
the tubes carefully, blood samples were centrifuged (10min, 1000×g), 
and blood plasma was collected and stored at − 20 ◦C. Following treat-
ments, mice were observed daily and were weighted every third day. At 
day 18 post-mating, pregnant females were separated into single cages 
to rear their offspring. Pregnant mice gave birth on days 20–22. Data on 
fertility, litter size, neonatal mortality, postnatal mortality and the 
clinical state of dams and pups were recorded daily. Dams and pups were 
observed for at least 2 weeks, before they were euthanized in a chamber 
by isoflurane/CO2. 
2.7. Measurements of BKI-1748 concentration in mouse plasma 
The methods for measurement of plasma BKI concentrations have 
been previously described (Hulverson et al., 2019). Briefly, BKI-1748 
was extracted from plasma using acetonitrile/0.1% formic acid with 
an internal standard and a standard curve was prepared for quantifica-
tion. All LC-MS/MS analytes were measured with an Acquity ultra per-
formance liquid chromatography (UPLC) system in tandem with a Xevo 
TQ-S micro mass spectrometer (Waters, Milford, MA, USA). 
2.8. Evaluation of BKI-1748 treatment effects in BALB/c mice infected 
with NcSpain-7 tachyzoites 
34 female and 17 male BALB/c mice, 8 weeks of age, were used. 
Mating was done as described under 2.6. Subsequently, females were 
randomly distributed into 3 groups: BKI-1748, BKI-1748+infection (n =
14); C+, corn oil + infection (n = 14); C-, corn oil alone (n = 6). Three 
days prior to infection, NcSpain-7 tachyzoites were transferred from HFF 
to BALB/c fibroblasts and cultured at 37 ◦C/5% CO2 (Aguado-Martínez 
et al., 2018). On day 7 post-mating, parasites were collected from cul-
ture flasks and counted as described (Arranz-Solís et al., 2015), and 105 
tachyzoites/100μl/mouse were injected subcutaneously. Group C- was 
inoculated with BALB/c dermal fibroblasts. At 2 days post-infection (p. 
i.), treatment with BKI-1748 suspended in corn oil at 20 mg/kg/day for 5 
days, or with corn oil alone, was initiated. Pregnant mice were 
Fig. 1. Structure and in vitro activities of BKI-1748 against N. caninum (Nc-β-gal) and T. gondii (Tg-β-gal). (A) molecular structure of BKI-1748, MW = molecular 
weight; EC50 = concentration of half maximal proliferation inhibition; *toxicity levels against human foreskin fibroblasts (HFF) and zebrafish embryos were 
determined previously [22]. (B,C) Dose-response curves for Neospora and Toxoplasma tachyzoites grown in HFF. 
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distributed into single cages at day 18 post-mating and non-pregnant 
mice were maintained in cages of 3–4 animals. Mice were evaluated 
for clinical signs, litter size, neonatal and postnatal mortality. All mice 
were euthanized 4 weeks post-partum (p.p.) as described above. Blood 
and brain samples were collected. IgG1-and IgG2a-levels were assessed 
by ELISA (Debache et al., 2008, 2009; Aguado-Martínez et al., 2016). 
Fig. 2. Immunofluorescence staining of HFF monolayers infected with N. caninum NcSpain-7 (A) and T. gondii Me49 tachyzoites (B) after treatment with 2.5 μM BKI- 
1748 for 2, 6 and 9 days. As a control, HFF were infected with the respective parasites but not treated and were fixed and stained after 2 days of incubation at 37 ◦C/ 
5% CO2. SAG1 is labelled in green, anti-IMC1 staining is red, and nuclei are stained blue with DAPI. (For interpretation of the references to colour in this figure 
legend, the reader is referred to the Web version of this article.) 
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2.9. BKI-1748 efficacy assessment in CD1 mice orally infected with 
TgShSp1 oocysts 
29 female and 15 male CD1 mice, 8 weeks of age, were used. 
Following mating, all females were randomly distributed into 3 exper-
imental groups: BKI-1748, BKI-1748+infection (n = 12); C+, corn oil +
infection (n = 12); C-, corn oil alone (n = 5). Infections were carried out 
with 50 TgShSp1 oocysts at day 7 post-mating, the C- group received 
PBS only. Treatments and separation of pregnant and non-pregnant mice 
were done as described above. All mice were monitored clinically for 4 
weeks p.p. Following euthanasia, blood, brain and eye samples were 
collected. Total IgG was measured in T. gondii infected mice by ELISA 
(Sánchez-Sánchez et al., 2019b). 
2.10. Determination of cerebral parasite load by real-time PCR 
Quantification of the cerebral parasite load in non-pregnant mice, 
dams and pups was done by real-time PCR methods designed specifically 
for either N. caninum (Müller et al., 2002; Aguado-Martínez et al., 2018) 
or T. gondii (Costa et al., 2000). For DNA purification the NucleoSpin 
Fig. 3. SEM micrographs of N. caninum tachyzoites and MNCs after exposure of infected HFF with BKI-1748. (A,B) non-treated tachyzoites, (C–F) BKI-1748 treated 
MNCs. The framed area in (A) is enlarged in (B), and the framed area in (E) is shown at higher magnification in (F); api = apical complex, small arrows point towards 
tachyzoites, the horizontal arrows indicate the conoid. Bars in (A) = 2.4 μM; (B) = 0.35 μm; (C) = 0.45 μm; (D) = 0.6 μm; (E) = 0.9 μm; (F) = 0.35 μM. 
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DNA RapidLyse Kit (Macherey-Nagel, Oensingen, Switzerland) was used 
according to standard protocols and DNA concentrations were quanti-
fied using the QuantiFluor double-stranded DNA (dsDNA) system 
(Promega, Madison, WI, USA). Quantitative real-time PCR was per-
formed with the Light Cycler (Roche, Basel, Switzerland), and parasite 
loads were calculated with a standard curve of DNA samples from 1′000, 
100, 10 N. caninum or T. gondii tachyzoites included in each run. 
2.11. Statistical analysis 
Statistical analysis of cerebral and ocular parasite burdens and 
antibody titers were compared between groups by the non-parametric 
Fig. 4. Transmission electron microscopy of N. caninum tachyzoites and MNCs. TEM micrographs of tachyzoites within a parasitophorous vacuole (A), and MNCs 
after 24 h (B,C), 48 h (D) and 72 h of exposure to BKI-1748 (E,F). (F) is a higher magnification view of (E); T indicates individual tachyzoites in BKI-treated cultures; 
n = nucleus; v = cytoplasmic vacuole; large arrows point towards newly formed apical complexes, dg = dense granules; rop = rhoptries; mito = mitochondrion; mic 
= micronemes; px = parasitophorous vacuole matrix; apg = amylopectin granules; small arrows indicate separation between nuclear membrane and the cytoplasm. 
Bars in (A) = 1.2 μm; (B) = 0.8 μm; (C) = 0.6 μm; (D) = 0.25 μm; (E) = 0.5 μm; (F) = 0.3 μm. 
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Kruskal-Wallis test, followed by Mann-Whitney-U test. The pup mor-
tality along time was compared by plotting survival events at each time 
point in Kaplan-Meier graphs and survival curves were compared by the 
Log-rank (Mantel-Cox) test. Statistical analysis was performed using 
Graphpad Prism version 9.0.2 for MacOSX (GraphPad Software, La 
Jolla, CA, USA). 
Fig. 5. TEM micrographs of N. caninum 
MNCs after 96 h treatment with BKI- 
1748. (A) is a low magnification view 
of an MNC infected human foreskin 
fibroblast, the framed areas are magni-
fied in (B) and (C). (B) shows a cluster of 
nuclei, surrounded by secretory organ-
elles and amylopectin granules, and 
micronemes are also arranged in tightly 
packed clusters: n = nucleus; v = cyto-
plasmic vacuole, large arrows point to-
wards apical complexes, dg = dense 
granules; rop = rhoptries; mito = mito-
chondrion; mic = micronemes; px =
parasitophorous vacuole matrix; apg =
amylopectin granules; small arrows 
indicate separation between nuclear 
membrane and the cytoplasm. Scale 
bars in (A) = 2 μm; (B) = 0.5 μm; (C) =
0.75 μm; (D) = 0.6 μm.   
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3. Results 
3.1. In vitro activities of BKI-1748 
Different compound concentrations were added to HFF concomi-
tantly to infection with Nc-β-gal or Tg-β-gal tachyzoites. The EC50 was 
165 nM for N. caninum and 43 nM for T. gondii (Fig. 1). In agreement 
with previous studies (Anghel et al., 2020), the viability of uninfected 
HFF was not impaired by BKI-1748 up to a concentration of 20 μM. 
Immunofluorescence staining of N. caninum (Fig. 2A) or T. gondii 
infected HFF (Fig. 2B), demonstrated that BKI-1748 treatment did not 
just inhibit proliferation of tachyzoites but induced the formation of 
intracellular multinucleated complexes (MNCs), similar to what has 
been observed earlier with BKI-1294 (Winzer et al., 2020b). These MNCs 
were enclosed by the major surface antigen SAG1 and contained zoites 
that underwent active proliferation, as evidenced by labeling with an 
antibody directed against the inner membrane complex 1 (IMC1). 
Fractions that were enriched for N. caninum MNCs were prepared, 
fixed and processed for SEM. MNCs were 2–6 μm in diameter and were 
comprised of a large parasitic mass with multiple protruding apical 
complexes displaying a conoid (Fig. 3). 
TEM confirmed the presence of viable zoites within these MNCs. 
Zoites exhibited an apical complex and the typical secretory organelles 
such as micronemes, rhoptries and dense granules (Fig. 4). After 24 h of 
treatment, there were still HFF harboring numerous individual tachy-
zoites, indicating that parasite proliferation was taking place initially, 
but some parasites exhibited structural alterations such as increased 
mass, more than one nucleus, vacuolization, and few newly formed 
apical complexes (Fig. 4B and C). After 48 h, MNCs showed increased 
numbers of nuclei (Fig. 4D), mitochondria lost their distinct electron 
dense matrix, and dissolving cristae became evident. Many of the nu-
clear membranes were physically separated from the cytoplasm. How-
ever, individual parasites were still visible in some cells (Fig. 4D). After 
72 h, larger complexes filled with newly emerged apical complexes were 
found, and the aberrant spacing between nuclei and cytoplasm was more 
evident (Fig. 4E and F). Nuclei were clustered centrally, and dense 
granules, micronemes and rhoptries were found more frequently in the 
periphery. In addition, the cytoplasm exhibited vesicles filled with 
electron-dense material of unknown nature, and the matrix of the par-
asitophorous vacuole contained granular and filamentous structures. 
After 96 h (Fig. 5), complexes became massive and occupied a large part 
of the host cell cytoplasm. These larger MNCs also contained amylo-
pectin granules. Dense granules were among the most abundant or-
ganelles, and the matrix of the parasitophorous vacuole was packed with 
vesicular and granular material (Fig. 5A–C). As shown in Fig. 5D, larger 
MNCs exhibited a polarized distribution of newly formed nuclei on one 
side, and typical apicomplexan secretory organelles on the other side. 
3.2. Safety during pregnancy in mice 
In order to investigate whether BKI-1748 interferes in pregnancy 
outcome, BALB/c mice were mated and received daily oral applications 
of BKI-1748 emulsified in corn oil at dosages of 50 mg/kg, 20 mg/kg or 
5 mg/kg on days 9–13 post-mating. In the group that received 50 mg/kg, 
only five pups were born alive, and one died within 24 h after birth, 
documenting a negative influence of pregnancy outcome (Anghel et al., 
2020). In contrast, in the groups treated with 20 mg/kg/day or 5 
mg/kg/day, no interference in pregnancy compared to the control group 
was noted (Table 1). 
Drug exposure at the two lower doses was further evaluated by 
determination of plasma drug concentrations (Fig. 6). Plasma concen-
trations were below the level of detection in the 5 mg/kg/day group, but 
mice treated with 20 mg/kg reached concentrations of 0.9–2.9 μM 
(Fig. 6). These levels were 6–17.5 times higher than the EC50 for 
N. caninum and 23–67.4 times higher than the EC50 for T. gondii. 
3.3. Efficacy of BKI-1748 in BALB/c mice infected with N. caninum 
tachyzoites 
The results of this experiment are summarized in Table 2. None of the 
dams exhibited clinical signs of neosporosis. Reproductive parameters 
such as fertility rate or litter size were not altered by the treatment. 
However, BKI-1748 had a profoundly favorable impact on pup survival 
(Fig. 7A). Neonatal pup mortality was observed in 2 out of 36 pups born 
in the BKI-1748 group and 2 out of 48 pups in the C- group, but postnatal 
mortality was 100% in the C+ group, while only 29.4% (10 out of 34 
pups) in the BKI-1748 group (Table 2). ELISA showed that all adult mice 
had undergone seroconversion. In pregnant animals, IgG1 and IgG2a 
antibody titers were significantly reduced in the BKI-1748 group 
compared to the C+ group, while in non-pregnant mice only IgG1 
antibody levels were significantly lower (Suppl. file 1). 
5 of 7 brain samples of the BKI-1748-treated dams and all 8 brains in 
the C+ group were Neospora PCR-positive (Table 2). The parasite loads 
in the C+ group were similar to the BKI-1748 group in pregnant and 
non-pregnant mice (Fig. 7B and C). Vertical transmission in the BKI- 
1748 treated group was detected in 41% of pups, while all pups tested 
positive in the C+ group. In non-pregnant mice, N. caninum DNA was 
detected in 4 out of 7 animals in the BKI-1748 group, and in 5 out of 6 
Table 1 
Potential pregnancy interference of BKI-1748 in embryo development.  















3/6 3/6 14 0/14 0/14 
20 mg/kg 
BKI-1748 
4/6 2/6 20 0/20 0/20 
50 mg/kg 
BKI-1748 
3/6 3/6 5 1/5 0/4 
Corn oil 3/6 3/6 23 1/23 0/22  
Fig. 6. BKI-1748 concentrations measured 1 h after the final treatment at day 5 
of 5 mg/kg/day and 20 mg/kg/day. For each dosage, blood of six mice was 
retrieved through the tail vein and blood plasma was collected to measure the 
drug concentration by LC-MS/MS. 
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mice in the C+ group (Table 2). Thus, BKI-1748 treatment did not 
inhibit brain infection in adult mice, but significantly inhibited vertical 
transmission of N. caninum. 
3.4. Efficacy of BKI-1748 treatment in CD1 mice infected with T. gondii 
oocysts 
The results of this experiment are summarized in Table 3. Oocyst 
infection did not result in clinical signs, and reproductive parameters 
were not affected. A major difference was seen in neonatal mortality 
(within 2 days p.p.), which was zero in the BKI-1748 group and 40% (37 
out of 92 pups) in the C+ group. Four pups in the BKI-1748 treatment 
group died during the first 16 days of the 1-month follow-up phase, 
while no postnatal mortality was noted for the C+ group (Fig. 8A). 
Increased IgG levels were detected in all infected mice, and IgG titers of 
BKI-1748 treated mice compared to C+ group animals were similar. 
(Suppl. file 2). In the C+ group 55 pups survived, of which 35 (64%) 
were PCR-positive. In the BKI-1748 group 67 pups survived, all of which 
were PCR negative. In the adult mice, brain infection was noted in 7 of 
12 BKI-1748 treated mice and in 11 of 12 C+ group mice (Table 3). 
Table 2 
Litter size, parasite burden, neonatal and postnatal mortality rates of N. caninum infected mice treated with BKI-1748.  
Treatment Challenge Seropositive for 
N. caninum 
N. caninum brain 
positive non-pregnant 
mice 
N. caninum brain 
positive dams 
Number of 











14/14 4/7 5/7 36/7 2/36 10/34 14/34 
Corn oil 105 NcSp7 
tachyzoites 
14/14 5/6 8/8 48/8 2/48 46/46 46/46 
Corn oil BALB/c dermal 
fibroblasts 
0/6 0/2 0/4 19/4 1/19 0/18 0/18  
Fig. 7. BKI-1748 treatment in the pregnant 
neosporosis mouse model. (A) Survival curve of 
pups and cerebral parasite burden of non- 
pregnant mice (B) and dams (C). Survival rates 
at each time point were plotted in Kaplan-Meier 
graphs and curves were compared by the Log- 
rank (Mantel-Cox) test. Differences between 
BKI-1748 and positive control curves were highly 
significant (P < 0.0001). BALB/c mice were 
experimentally infected with 105 NcSpain-7 
tachyzoites and treated with BKI-1748 for 5 
days at 20 mg/kg/day in corn oil or were treated 
with corn oil alone (C+). C- was not infected and 
treated with corn oil only. Brains of all mice were 
collected directly after euthanasia and parasite 
burden of non-pregnant mice and dams was 
quantified by real-time PCR. Values are shown as 
box plots. No statistically significant differences 
in the cerebral parasite burden were observed 
between BKI-1748-treated mice compared to the 
C+ group (neither in non-pregnant mice nor in 
dams).   
Table 3 
Litter size, parasite burden, neonatal and postnatal mortality rates of T. gondii infected mice treated with BKI-1748.  
Treatment Challenge Seropositive for 
T. gondii 
T. gondii brain positive 
non-pregnant mice 
T. gondii brain 
positive dams 






T. gondii brain 
positive pups 




8/12 3/6 4/6 71/6 0/71 4/71 4/71 
Corn oil 50 TgShSp1 
oocysts 
9/12 4/4 7/8 92/8 37/92 0/55 35/55 
Corn oil PBS 0/5 0/2 0/3 41/3 0/41 0/41 0/41  
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However, quantification of the parasite load showed highly significant 
differences between the respective BKI-1748 and C+ groups (Fig. 8B and 
C). 
Toxoplasma DNA was also quantified in eye samples from all adult 
mice. Ocular infection was identified in 2 out of 6 dams in the BKI-1748 
group and in 5 out of 8 dams in the C+ group. In non-pregnant mice, 
ocular infection was strongly reduced in BKI-1748 treated non-pregnant 
mice contrary to the positive control, with 4 out of 4 mice exhibiting 
ocular infection (Fig. 9A). Toxoplasma eye infection in dams of the BKI- 
1748 group was not significantly reduced compared to the C+ group 
(Fig. 9B). 
4. Discussion 
This study describes the efficacy of the CDPK1 inhibitor BKI-1748 
against N. caninum and T. gondii in vitro and in experimentally infected 
mice. Our results indicate that BKI-1748 represents a promising addition 
to the growing arsenal of novel candidate compounds that could be 
developed for the treatment of congenital infection and disease inflicted 
by these two closely related parasites (Sánchez-Sánchez et al., 2018b; 
Smith et al., 2021). 
In vitro, BKI-1748 inhibited both N. caninum and T. gondii tachyzoite 
proliferation at nanomolar values. The T. gondii EC50 value (43 nM) was 
4-times lower compared to the EC50 measured for N. caninum (165 nM). 
BKI-1748 did not affect HFF at a concentration up to 20 μM, and did not 
induce cytotoxicity in human hepatocyte (HepG2) and lymphocyte 
Fig. 8. BKI-1748 treatment in the pregnant 
toxoplasmosis mouse model. (A) Survival curves 
of pups and cerebral parasite burden of non- 
pregnant mice (B) and dams (C). Survival rates 
at each time point were plotted in Kaplan-Meier 
graphs and curves were compared by the Log- 
rank (Mantel-Cox) test. Differences between 
BKI-1748 and positive control curves were highly 
significant (P < 0.0001). CD1 mice were infected 
with 50 oocysts of the TgShSp1 strain and treated 
with 20 mg/kg BKI-1748, while C+ was infected 
and treated with corn oil alone. C- was not 
infected and treated with corn oil only. All mice 
were euthanized 30 days p.p. After euthanasia, 
brains were aseptically collected, and cerebral 
parasite burden of non-pregnant mice and dams 
was quantified by real-time PCR. Values are 
depicted as box plots. Parasite burden between 
groups were compared by the Kruskal-Wallis test, 
followed by the Mann-Whitney-U test. Differ-
ences between BKI-1748-treated and non-treated 
groups were statistically significant (*P < 
0.0127, **P < 0.0095).   
Fig. 9. Ocular parasite burden of non-pregnant 
mice (A) and dams (B) infected with 50 oocysts 
of the TgShSp1 strain and treated with BKI-1748 
at 20 mg/kg/day for 5 days, or with corn oil 
alone (C+). C- was not infected and treated with 
corn oil only. Eyes were removed after eutha-
nasia and DNA was extracted and quantified by 
real-time PCR. Values are shown in box plots. 
Ocular parasite burden between groups were 
compared by the Kruskal-Wallis test, followed by 
the Mann-Whitney-U test. Differences between 
BKI-1748-treated and non-treated groups were 
statistically significant in non-pregnant mice 
(**P < 0.0048) but not in dams.   
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(CRL-8155) cell lines (Anghel et al., 2020). Microscopy demonstrated 
that in vitro treatment with BKI-1748 at 2.5 μM did not rapidly kill 
tachyzoites, but, as seen earlier for other BKIs (Winzer et al., 2015, 
2020b; Müller et al., 2017b), exposure to BKI-1748 resulted in the 
appearance of MNCs, which grew considerably with increasing duration 
of treatment. DNA replication and nuclear division obviously took place 
in these complexes, but the final steps in cytokinesis were blocked, and 
newly formed zoites, lacking the major tachyzoite surface antigen SAG1 
but expressing IMC1, were trapped within their host cell. While these 
zoites exhibited some structural alterations, they remained largely 
viable upon continuous treatment for several days to weeks. 
Multinucleated forms were also reported upon BKI-treatment of the 
related apicomplexans Sarcocystis neurona and Besnoitia besnoiti (Ojo 
et al., 2017; Jiménez-Meléndez et al., 2017). A detailed study on 
N. caninum MNCs that formed upon treatment with the related PP 
compound BKI-1294 showed that upon drug removal parasites resumed 
their cell cycle and formed infective tachyzoites that re-emerged out of 
these complexes within 10 days (Winzer et al., 2020b). Overall, MNCs 
are regarded as a drug-induced stage that ensures survival of the parasite 
under drug pressure, and comparative proteomics had shown that only 
12 proteins were expressed at higher levels in MNCs compared to 
tachyzoites (Winzer et al., 2020c). Among them were the bradyzoite 
antigens NcSAG4 and NcBSR4, and other proteins comprised of signal 
peptides and SRS domains. In addition, mRNA coding for NcBAG1, 
another bradyzoite marker, was highly expressed in MNCs but not in 
tachyzoites (Winzer et al., 2015, 2020c). There is evidence that the 
formation of MNCs also affects the cellular and humoral immune 
response and could have an impact in terms of re-infection during 
pregnancy in previously infected animals (Winzer et al., 2020a). 
Whether MNCs induced by the AC compound BKI-1748 exhibit a similar 
pattern of upregulated proteins has not been investigated so far. 
It was shown previously that exposure of zebrafish embryos to BKI- 
1748 at concentrations of 10 μM or below did not interfere directly in 
embryo development (Anghel et al., 2020). This information is impor-
tant for drugs to be applied during pregnancy. BKI-1748 clearly inter-
fered in pregnancy outcome when applied at 50 mg/kg from days 9–13 
of pregnancy (Anghel et al., 2020), a regimen that had been demon-
strated to be safe for BKI-1294 treatments (Winzer et al., 2015). How-
ever, dosages of 20 and 5 mg/kg/day, did not lead to adverse effects in 
dams or pups. Determination of BKI-1748 plasma levels in mice treated 
with 20 mg/kg/day (0.9–2.9 μM) were well below the 10 μM that could 
potentially exert embryotoxicity. Thus, a dosage of 20 mg/kg/day for 5 
days was chosen for treatment studies in the neosporosis and toxoplas-
mosis mouse models. 
In both models, BKI-1748 was highly efficacious in preventing ver-
tical transmission and clinical signs in pups. BKI-1748 appeared more 
efficacious in the Toxoplasma model compared to the Neospora model. 
However, direct comparisons should not be made. T. gondii infection was 
performed in outbred CD1 mice by oral gavage of 50 oocysts of the 
TgShSp1 strain (Sánchez-Sánchez et al., 2019b). This infection dose had 
been previously determined in a small pilot experiment not to cause 
clinical signs in dams but to still provide sufficient vertical transmission 
(data not shown). On the other hand, 105 N. caninum tachyzoites were 
used to infect inbred BALB/c mice by subcutaneous injection. In the 
former, a relatively small number (approx. 400) of infective sporozoites 
were inoculated, which required some time to disseminate and differ-
entiate into the proliferative form that causes disease; in the latter, a 
much higher number of infective tachyzoites was likely to disseminate 
much more rapidly, leading to a higher parasite burden within a shorter 
time frame. 
Overall, treatment with BKI-1748 in the neosporosis model was less 
efficacious compared to the previously reported studies on BKI-1294 
(Winzer et al., 2015, 2020a), but clearly superior in terms of safety 
and efficacy compared to BKI-1553 and BKI-1517 (Müller et al., 2017b), 
respectively. In contrast to the neosporosis model, the cerebral parasite 
loads of Toxoplasma infected adult mice in BKI-1748-treated versus C+
groups were significantly reduced. This difference in efficacy in adult 
mice could also be related to the inherent differences in the life cycle 
stages, the infection dose, and the route of infection. 
With regard to the toxoplasmosis mouse model used here, BKI-1748 
appeared to exhibit some advantages compared to BKI-1294. BKI-1294 
had been assessed in a T. gondii Me49 oocyst infection model. In that 
study, the number of BKI-1294-treated CD1 dams that gave birth to 
offspring was reduced by 50% compared to the control, which implied a 
negative impact on fertility in that particular mouse strain, posing some 
potential safety issues (Müller et al., 2017a). In terms of vertical trans-
mission, however, BKI-1294 also conferred a similarly high degree of 
protection. However, the PP-compound BKI-1294 was found to exhibit a 
high hERG liability, which would preclude its use in humans due to 
safety issues (Choi et al., 2020). BKI-1748 is structurally based on an AC 
scaffold. AC scaffold compounds were shown to elicit lower affinity for 
hERG compared to BKIs with a PP scaffold (Choi et al., 2020), rendering 
this compound more safe and more promising. 
In conclusion, the novel CDPK1 inhibitor BKI-1748 is an auspicious 
compound with proven in vitro activity and in vivo efficacy against both 
apicomplexan parasites N. caninum and T. gondii. Based on these results, 
BKI-1748 should be considered as a candidate for further assessments in 
pregnant neosporosis and toxoplasmosis ruminant models. 
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